We are excited to share that our client Xenikos has been approved by the U.S. FDA for the trial use of a newly developed drug, T-Guard, in treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation. Xenikos is a biopharmaceutical company based in The Netherlands focused on the development of immunotherapies designed to safely reset the immune system in patients with severe immune diseases or following post-transplant rejection.
One of our specialties at Newman & Lickstein, LLP is helping life science & biotechnology professionals navigate through the pivotal moments of their corporate lifecycle to achieve their most critical business and legal goals.
Please read the linked article to learn more:
